Brummer & Partners, the long-running Swedish multi-strategy hedge fund firm, is maintaining its market neutral approach and focus on diversification after its flagship strategy stumbled during the recent steep market sell-off. In a note to investors this week, founder Patrik
By Don Steinbrugge, Agecroft Partners – The changing landscape caused by the Coronavirus will lead to the largest shake out in the hedge fund industry since the 2008 market crash. Below are some of the ways we believe the Coronavirus
The market fallout from the coronavirus pandemic will see continued volatility across equity, credit and commodity markets – but also potential investment opportunities.
The European Securities and Markets Authority, the pan-EU financial watchdog, tightened rules on short-selling on Monday, and will now require hedge funds and other holders of net short positions to notify their respective national regulators of positions greater than 0.1
A stronger revalued yuan is vital to any post-coronavirus global economic recovery, with reinvigorated Chinese financial firepower helping to swerve a deep recession in the next year, according to Toscafund Asset Management’s Savvas Savouri.
Despite extreme levels of market volatility, increased trading volumes and disruptions to society due to Covid-19, alternative fund managers have persevered, and even exceeded, performance expectations from investors.Nonetheless, managers continue to face challenges in addressing important areas of focus, including
By Kieran Fox, Irish Funds – We are all well aware of the human and public health cost which Covid-19 has had since March of this year when its impact reverberated around the globe. Although general consensus is that we
The prospect of remote working becoming the “new normal” amid the likelihood of renewed Covid-19 lockdowns is driving investment managers of all sizes and strategies to re-evaluate their operational infrastructure and business practices in light of this year’s unprecedented events,
The frantic hunt for an effective vaccine against coronavirus could leave some pharmaceutical companies highly exposed in a fiercely competitive race – and UK hedge fund Argonaut Capital is weighing in with several key bets against the sector.
In his latest blog Joel Press, formerly a senior partner and Head of the Global Hedge Fund Practice at Ernst & Young, and a leading voice on hedge fund operations and co-ordination services, considers the ‘new normal’ of flexible working, virtual
